Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386979894> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W4386979894 abstract "Abstract Background Erythropoietic effects of molidustat, a hypoxia‐inducible factor prolyl hydroxylase (HIF‐PH) inhibitor, were previously demonstrated in healthy cats. Objective To evaluate the safety and erythropoietic effects of daily PO administration of molidustat in anemic cats with chronic kidney disease (CKD). Animals Twenty‐one client‐owned CKD cats (4‐17 years old) with anemia. Methods Multicenter field study; randomized, masked, and placebo‐controlled. Cats were treated PO once daily for 28 days with suspensions of control product (CP; n = 6) or 5 mg/kg of molidustat (n = 15). Hematocrit (HCT) was evaluated at weekly intervals. Individual cat treatment success was defined as a ≥4% point increase in HCT compared to baseline. Results Control group mean HCT remained low throughout the study (20.1%‐23.4%). Mean HCT of molidustat‐treated cats increased weekly, and a significant increase compared to baseline (23.6%) was first observed on Day 21 (27.3%; P < .001; 95% confidence interval [CI], 1.69‐5.67). Compared to CP group, mean HCT was significantly higher on Day 21 (27.3% vs 20.1%; P < .001; 95% CI, 2.91‐10.75) but not significantly higher on Day 28 (27.8% vs 23.4%; P = .06; 95% CI, −0.23 to 9.88). The number of individual treatment successes on Day 28 was higher among remaining molidustat‐treated cats (7/14) compared to remaining control cats (1/5), but there was no significant difference between groups. Conclusions and Clinical Importance Daily PO molidustat administration may stimulate a clinically relevant erythropoietic response in anemic cats with CKD. This HIF‐PH inhibitor may be an alternative for managing anemia in cats compared to recombinant EPO treatment." @default.
- W4386979894 created "2023-09-24" @default.
- W4386979894 creator A5011739775 @default.
- W4386979894 creator A5030532444 @default.
- W4386979894 creator A5064018031 @default.
- W4386979894 creator A5076103103 @default.
- W4386979894 creator A5092926683 @default.
- W4386979894 date "2023-09-22" @default.
- W4386979894 modified "2023-10-10" @default.
- W4386979894 title "Use of molidustat, a hypoxia‐inducible factor prolyl hydroxylase inhibitor, in chronic kidney disease‐associated anemia in cats" @default.
- W4386979894 cites W1838371190 @default.
- W4386979894 cites W2053927571 @default.
- W4386979894 cites W2054833761 @default.
- W4386979894 cites W2080322097 @default.
- W4386979894 cites W2081574969 @default.
- W4386979894 cites W2087830638 @default.
- W4386979894 cites W2504393479 @default.
- W4386979894 cites W2583827410 @default.
- W4386979894 cites W2593244426 @default.
- W4386979894 cites W2805331176 @default.
- W4386979894 cites W3137112841 @default.
- W4386979894 cites W3146152685 @default.
- W4386979894 doi "https://doi.org/10.1111/jvim.16807" @default.
- W4386979894 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37740521" @default.
- W4386979894 hasPublicationYear "2023" @default.
- W4386979894 type Work @default.
- W4386979894 citedByCount "0" @default.
- W4386979894 crossrefType "journal-article" @default.
- W4386979894 hasAuthorship W4386979894A5011739775 @default.
- W4386979894 hasAuthorship W4386979894A5030532444 @default.
- W4386979894 hasAuthorship W4386979894A5064018031 @default.
- W4386979894 hasAuthorship W4386979894A5076103103 @default.
- W4386979894 hasAuthorship W4386979894A5092926683 @default.
- W4386979894 hasBestOaLocation W43869798941 @default.
- W4386979894 hasConcept C126322002 @default.
- W4386979894 hasConcept C134018914 @default.
- W4386979894 hasConcept C142724271 @default.
- W4386979894 hasConcept C204787440 @default.
- W4386979894 hasConcept C27081682 @default.
- W4386979894 hasConcept C2778248108 @default.
- W4386979894 hasConcept C2778534260 @default.
- W4386979894 hasConcept C2778653478 @default.
- W4386979894 hasConcept C2779904517 @default.
- W4386979894 hasConcept C2780959883 @default.
- W4386979894 hasConcept C44249647 @default.
- W4386979894 hasConcept C71924100 @default.
- W4386979894 hasConcept C90924648 @default.
- W4386979894 hasConceptScore W4386979894C126322002 @default.
- W4386979894 hasConceptScore W4386979894C134018914 @default.
- W4386979894 hasConceptScore W4386979894C142724271 @default.
- W4386979894 hasConceptScore W4386979894C204787440 @default.
- W4386979894 hasConceptScore W4386979894C27081682 @default.
- W4386979894 hasConceptScore W4386979894C2778248108 @default.
- W4386979894 hasConceptScore W4386979894C2778534260 @default.
- W4386979894 hasConceptScore W4386979894C2778653478 @default.
- W4386979894 hasConceptScore W4386979894C2779904517 @default.
- W4386979894 hasConceptScore W4386979894C2780959883 @default.
- W4386979894 hasConceptScore W4386979894C44249647 @default.
- W4386979894 hasConceptScore W4386979894C71924100 @default.
- W4386979894 hasConceptScore W4386979894C90924648 @default.
- W4386979894 hasLocation W43869798941 @default.
- W4386979894 hasLocation W43869798942 @default.
- W4386979894 hasOpenAccess W4386979894 @default.
- W4386979894 hasPrimaryLocation W43869798941 @default.
- W4386979894 hasRelatedWork W1786763232 @default.
- W4386979894 hasRelatedWork W2091329577 @default.
- W4386979894 hasRelatedWork W2098830437 @default.
- W4386979894 hasRelatedWork W2121791471 @default.
- W4386979894 hasRelatedWork W2137584496 @default.
- W4386979894 hasRelatedWork W2167902350 @default.
- W4386979894 hasRelatedWork W2366700700 @default.
- W4386979894 hasRelatedWork W2367281640 @default.
- W4386979894 hasRelatedWork W2805683016 @default.
- W4386979894 hasRelatedWork W2404988978 @default.
- W4386979894 isParatext "false" @default.
- W4386979894 isRetracted "false" @default.
- W4386979894 workType "article" @default.